ERBB2 and colorectal carcinoma: Amplification of HER2 only accounts for approximately 3% of CRC patients [4, 5], increasing up to 5% in KRAS exon 2 WT tumors and 5.2% in KRAS/BRAF WT patients at stage IV [6, 7].